CD19 is a transmembrane glycoprotein expressed on all B-lineage cells throughout B cell development. It’s critically important for B cell function and cell survival and regulates B cell receptor (BCR) signaling. Studies show that CD19 promotes BCR-dependent survival signals in mature B cells and also promotes survival of naïve recirculating B cells.1
CD19 is an attractive target for treatment because it is expressed on the majority of B cell malignancies, with approximately 85% of non-Hodgkin lymphoma cases originating in B cells.2
Search our clinical trials.
Download additional information from our resources section.
CD: cluster of differentiation.
1. Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas. Am J Cancer Res. 2016;6(2):403-424.2. American Cancer Society. Types of B-cell lymphoma. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html. Accessed 4/5/2019.